Shenzhen Neptunus Bioengineering Co

Shenzhen Neptunus Bioengineering Co Capital Expenditures

The Capital Expenditures (CapEx) of Shenzhen Neptunus Bioengineering Co (000078.SZ) as of Oct 28, 2026 is -127.09 M CNY. In the previous year, Capital Expenditures (CapEx) was -84.60 M CNY — a change of 50.22% (lower).

Capital Expenditures

-127.09 MCNY

YoY

50.22%

Last updated:

Capital Expenditures (CapEx) of Shenzhen Neptunus Bioengineering Co is 2025 -127.09 M CNY. Capital Expenditures (CapEx) of Shenzhen Neptunus Bioengineering Co was 2024 -84.60 M CNY. It decreases by 50.22% lower compared to the previous year.

The Shenzhen Neptunus Bioengineering Co Capital Expenditures history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Capital Expenditures
Date
Capital Expenditures
Jan 1, 2018
-213.51 M CNY
Jan 1, 2019
-167.53 M CNY
Jan 1, 2020
-147.29 M CNY
Jan 1, 2021
-129.23 M CNY
Jan 1, 2022
-94.32 M CNY
Jan 1, 2023
-104.07 M CNY
Jan 1, 2024
-84.60 M CNY
Jan 1, 2025
-127.09 M CNY
The Shenzhen Neptunus Bioengineering Co Capital Expenditures history
YEARCapital ExpendituresYoY
-127.09 MCNY+50.22%
-84.60 MCNY-18.71%
-104.07 MCNY+10.34%
-94.32 MCNY-27.01%
-129.23 MCNY-12.27%
-147.29 MCNY-12.08%
-167.53 MCNY-21.53%
-213.51 MCNY-21.66%
-272.54 MCNY-3.71%
-283.06 MCNY+66.26%
-170.25 MCNY-28.04%
-236.59 MCNY—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Shenzhen Neptunus Bioengineering Co Stock analysis

What does Shenzhen Neptunus Bioengineering Co do? Shenzhen Neptunus Bioengineering Co., Ltd. generates revenue through its pharmaceutical products and healthcare offerings. The company produces anti-tumor products, cardiovascular drugs, marine drugs, respiratory drugs, anti-infective products, and other pharmaceuticals. It also sells healthcare products, health food, and medical instruments. The primary market for these products is the domestic market, with East China being the main regional focus. The company serves healthcare providers, hospitals, and consumers within China's pharmaceutical sector. Neptunus targets the Chinese domestic market, emphasizing East China as its core region. Its product portfolio spans multiple therapeutic areas including oncology, cardiology, respiratory care, and infection control. The company's distribution network focuses on reaching hospitals and healthcare facilities across China, particularly in the East China region. The firm's health food and medical instrument lines complement its pharmaceutical business, creating diversified revenue streams within the healthcare industry. The business model relies on selling established pharmaceutical products alongside healthcare and medical solutions. Anti-tumor products and cardiovascular drugs form key segments of its revenue, supported by marine drugs and respiratory medications. East China's dominance in sales reflects the company's strategic market focus. The company's full-time employee count of 9,874 supports its manufacturing and distribution operations across China's domestic market. Shenzhen Neptunus Bioengineering Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Shenzhen Neptunus Bioengineering Co stock

Capital Expenditures (CapEx) of Shenzhen Neptunus Bioengineering Co is -127.09 M CNY in 2025.

Capital Expenditures (CapEx) of Shenzhen Neptunus Bioengineering Co changed from -84.60 M CNY to -127.09 M CNY, representing a 50.22% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Capital Expenditures (CapEx) Shenzhen Neptunus Bioengineering Co since 2006 – with annual values, charts, and detailed analysis.

Capital expenditures represent investments in long-term assets such as property, equipment, and technology. CapEx is essential for maintaining and growing the business.

Capital Expenditures (CapEx)'s CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Capital Expenditures (CapEx)'s Shenzhen Neptunus Bioengineering Co historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Shenzhen Neptunus Bioengineering Co

All Key Metrics — Shenzhen Neptunus Bioengineering Co